• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Appoints Dirk Benson Chief Commercial Officer, North America Distribution Group

    5/17/22 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email

    Nancy Lanni, Experienced Health Care Leader, Named Vice President and General Manager, Strategic Account Management Team

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today the appointment of Dirk Benson to the position of Vice President and Chief Commercial Officer of the Company's North America Distribution Group (NADG).

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516006085/en/

    Dirk Benson, Vice President and Chief Commercial Officer, North America Distribution Group, Henry Schein. (Photo: Business Wire)

    Dirk Benson, Vice President and Chief Commercial Officer, North America Distribution Group, Henry Schein. (Photo: Business Wire)

    In this new position, Mr. Benson will drive Henry Schein's "One Distribution" initiative, a critical element of the Company's 2022-2024 BOLD+1 Strategic Plan. "One Distribution" is designed to more tightly integrate the management of Henry Schein's distribution businesses globally while more fully leveraging the functions, talent, processes, and systems of our distribution businesses to enhance the customer experience and maximize efficiency and performance.

    Mr. Benson will be responsible for the entire dental and medical customer-facing organization in the U.S. of the NADG, Henry Schein's largest business group. He will report to Brad Connett, Chief Executive Officer, North America Distribution Group.

    Prior to Henry Schein, Mr. Benson had a 27-year career with health care products distributor Medline Industries, LP, the largest privately held U.S. manufacturer and distributor of health care supplies. Mr. Benson retired from Medline in 2020 as a member of the company's Executive Committee. A native of Milwaukee, Wisconsin, and a graduate of Marquette University, Mr. Benson joined Medline in 1993 and held a series of increasingly responsible positions at the company.

    "Dirk is an outstanding professional," said Mr. Connett. "He is held in high regard in the industry, with a track record of growing innovative businesses and leading people. Dirk has a deep knowledge of health care distribution, experience building teams that work across boundaries, and the energy and insight needed to help Henry Schein fulfill our strategic plan."

    "I have long admired the success of Henry Schein, and I am excited to make a contribution to advancing the innovative growth strategy of this first-class company," said Mr. Benson. "The values of the organization, the dedication of Henry Schein's leadership, and the quality of the team are well-known in the health care industry. I am really pleased to be a part of Team Schein and to help our Company continue the extraordinary record of success."

    Mr. Benson's team will include the following experienced health care executives, each with a long history with Henry Schein:

    • Dave Steck, recently promoted to the position of Vice President and General Manager, U.S. Dental Group;
    • Ty Ford, Vice President and General Manager, U.S. Medical Sales;
    • Jeff Klingler, Vice President and General Manager, Enterprise Health; and
    • Jim Loiacono, Vice President, Telesales and Operational Support Services.

    In addition, Nancy Lanni has been named Vice President and General Manager of the newly created Strategic Account Management Team, responsible for serving the Company's large dental and medical distribution customers in the U.S. as a part of Mr. Benson's team. Ms. Lanni, who joined Henry Schein in 1995, has held increasingly responsible leadership positions at the Company, most recently as the head of the Healthcare Services team of the Company's U.S. Medical Group, serving the group's largest customers.

    "Nancy has done an extraordinary job with our medical strategic customers and has developed a particular expertise in working with the executive suite of large health care organizations," said Mr. Connett. "She has a deep understanding of the changing dynamics of our customers, and as the trend toward consolidation accelerates across the markets we serve, Nancy's insights and leadership capabilities will benefit the team, our customers, and our business."

    "I am pleased and honored by this new assignment, and I look forward to working with Brad, Dirk, and the NADG team to deepen our presence among strategic health care customers," said Ms. Lanni.

    "We are delighted to welcome an executive of Dirk's caliber to our management team and to congratulate Nancy on her expanded responsibilities," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein, Inc. "As we implement our 2022-2024 BOLD+1 Strategic Plan, we are focused on advancing our exceptional customer experience through the delivery of innovative services and solutions. Dirk and Nancy will further that goal as proven, growth-oriented leaders with deep experience in building effective sales teams and winning in markets undergoing transformation."

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With nearly 22,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories. The Company's sales reached $12.4 billion in 2021, and have grown at a compound annual rate of approximately 12.5 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220516006085/en/

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    More analyst ratings

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein to Participate in Upcoming Investor Conferences in March

    Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conferences in March: Leerink's Global Healthcare Conference at the W South Beach hotel, Miami, on March 9, at 10:00 a.m. EST. Barclays 28th Annual Global Healthcare Conference at the Loews Miami Beach hotel, Miami, on March 10, at 10:30 a.m. EST. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc. (NASDAQ:HSIC) is a so

    3/3/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

    Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced respo

    2/26/26 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 10-K filed by Henry Schein Inc.

    10-K - HENRY SCHEIN INC (0001000228) (Filer)

    2/24/26 4:42:20 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    2/24/26 6:14:45 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    1/12/26 7:00:12 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Lowery Frederick M. was granted 30,723 shares (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/3/26 5:02:16 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SVP & Chief Financial Officer South Ronald N. returned 6,815 shares to the company and covered exercise/tax liability with 709 shares, decreasing direct ownership by 9% to 73,850 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/3/26 8:30:13 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SVP, Chief Human Res. Officer Sheehy Christine Zayac returned 780 shares to the company and covered exercise/tax liability with 88 shares, decreasing direct ownership by 7% to 11,830 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/3/26 8:27:47 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

    Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results

    11/4/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care